Sacubitril/valsartan reduced cardiomyopathy risk by 77% in cancer patients on anthracycline chemotherapy, as shown in the SARAH trial. The trial involved 114 adults, primarily women with breast cancer ...
Researchers from the Germans Trias i Pujol research institute (IGTP) have conducted a preclinical study on the effects of the drug empagliflozin, alone or in combination with sacubitril/valsartan, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results